KHK2823 / Kyowa Kirin - LARVOL DELTA

Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Kyowa Hakko Kirin Pharma, Inc.; Trial primary completion date: Mar 2017 ➔ Dec 2017

Trial primary completion date • Acute Myelogenous Leukemia • Biosimilar • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - P1; N=39; Terminated; Sponsor: Kyowa Kirin Pharmaceutical Development, Inc.; N=60 ➔ 39; Active, not recruiting ➔ Terminated; Failed treatment response

Clinical • Enrollment change • Trial termination

Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - P1; N=60; Active, not recruiting; Sponsor: Kyowa Kirin Pharmaceutical Development, Inc.; Trial primary completion date: Mar 2019 ➔ Jul 2019

Clinical • Trial primary completion date